Pro-inflammatory immune microenvironment and Thrombospondin-1-positive monocytes as drivers of osteoclastogenesis in postmenopausal osteoporosis

J Bone Miner Res. 2025 Aug 24;40(9):1061-1076. doi: 10.1093/jbmr/zjaf083.

Abstract

Postmenopausal osteoporosis (PMOP) is driven by an imbalance in the interaction among osteoclasts, osteoblasts, and immune cells within the bone marrow microenvironment. However, detailed single-cell transcriptomic data on the bone microenvironment of PMOP patients are lacking. This study characterized the cellular landscape of the bone marrow in PMOP and identified key osteoclastogenic pathways. Single-cell RNA sequencing of bone marrow cells from 10 PMOP patients and 10 controls (totaling 93 867 cells) was performed, complemented by histological validation and in vitro modulation of key pathways. The findings revealed elevated expression of cytokines and chemokines in specific cell subpopulations, including hematopoietic stem cells, B cells, T cells, dendritic cells, neutrophils, granulocyte-macrophage progenitors, and erythroid cells, which are likely to contribute to the promotion of osteoclastogenesis. Enhanced differentiation of monocytes into osteoclasts was linked to elevated B cell communication. Furthermore, 3 monocyte subsets (THBS1+ with CCL20+, or LRP1+, or C1QA+) exhibited osteoclastogenic potential, associated with the activation of the Nucleotide-binding Oligomerization Domain (NOD)-like receptor pathway. Targeting THBS1 significantly reduced bone loss in PMOP mouse models. This study provides a detailed characterization of bone marrow cell heterogeneity in postmenopausal women, offering insights into potential therapeutic strategies targeting PMOP.

Keywords: NOD-like receptor signaling pathway; monocyte; osteoclastogenesis; postmenopausal osteoporosis; single-cells transcriptomic analysis.

Plain language summary

Postmenopausal osteoporosis (PMOP) leads to decreased bone density and increased fracture risk due to an imbalance in bone resorption and formation. In this study, we analyzed the bone marrow microenvironment of women with PMOP to identify cellular and molecular factors driving bone loss. Using single-cell RNA sequencing, we found that immune cells, including monocytes, contribute significantly to osteoclastogenesis, the process that breaks down bone tissue. Specifically, 3 subsets of monocytes, expressing THBS1 and other markers, were identified as key drivers of this process through activation of the NOD-like receptor pathway. Targeting these pathways in animal models reduced bone loss, offering potential therapeutic targets for PMOP.

MeSH terms

  • Aged
  • Animals
  • Cell Differentiation
  • Cellular Microenvironment* / immunology
  • Female
  • Humans
  • Inflammation* / immunology
  • Inflammation* / pathology
  • Mice
  • Middle Aged
  • Monocytes* / immunology
  • Monocytes* / metabolism
  • Monocytes* / pathology
  • Osteoclasts* / immunology
  • Osteoclasts* / metabolism
  • Osteoclasts* / pathology
  • Osteogenesis* / immunology
  • Osteoporosis, Postmenopausal* / genetics
  • Osteoporosis, Postmenopausal* / immunology
  • Osteoporosis, Postmenopausal* / metabolism
  • Osteoporosis, Postmenopausal* / pathology
  • Thrombospondin 1* / metabolism

Substances

  • Thrombospondin 1
  • thrombospondin-1, human